{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:26Z","timestamp":1789981286570,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Zika virus (ZIKV) causes significant public health concerns because of its association with congenital malformations, neurological disorders in adults, and, more recently, death. Considering the necessity to mitigate ZIKV-associated diseases, antiviral interventions are an urgent necessity. Sofosbuvir, a drug in clinical use against hepatitis C virus (HCV), is among the FDA-approved substances endowed with anti-ZIKV activity. In this work, we further investigated the\n                    <jats:italic>in vivo<\/jats:italic>\n                    activity of sofosbuvir against ZIKV. Neonatal Swiss mice were infected with ZIKV (2\u2009\u00d7\u200910\n                    <jats:sup>7<\/jats:sup>\n                    PFU) and treated with sofosbuvir at 20\u2009mg\/kg\/day, a concentration compatible with pre-clinical development of this drug. We found that sofosbuvir reduced acute levels of ZIKV from 60 to 90% in different anatomical compartments, such as the blood plasma, spleen, kidney, and brain. Early treatment with sofosbuvir doubled the percentage and time of survival of ZIKV-infected animals. Sofosbuvir also prevented the acute neuromotor impairment triggered by ZIKV. In the long-term behavioural analysis of ZIKV-associated sequelae, sofosbuvir prevented loss of hippocampal- and amygdala-dependent memory. Our results indicate that sofosbuvir inhibits ZIKV replication\n                    <jats:italic>in vivo<\/jats:italic>\n                    , which is consistent with the prospective necessity of antiviral drugs to treat ZIKV-infected individuals.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-09797-8","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T03:42:30Z","timestamp":1503286950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae"],"prefix":"10.1038","volume":"7","author":[{"given":"Andr\u00e9 C.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Zaverucha-do-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia A.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Barbosa-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine Rangel","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayara","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila de Paiva","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sacramento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo C.","family":"de Castro Faria Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loraine","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amilcar","family":"Tanuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando A.","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia T.","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago Moreno L.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"9797_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.03.001","volume":"308","author":"BH Song","year":"2017","unstructured":"Song, B. H., Yun, S. I., Woolley, M. & Lee, Y. M. Zika virus: history, epidemiology, transmission, and clinical presentation. J. Neuroimmunol. \n                           308, 50\u201364 (2017).","journal-title":"J. Neuroimmunol."},{"key":"9797_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1473-3099(16)00095-5","volume":"16","author":"G Calvet","year":"2016","unstructured":"Calvet, G. et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect. Dis. \n                           16, 653\u2013660 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"9797_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","volume":"387","author":"VM Cao-Lormeau","year":"2016","unstructured":"Cao-Lormeau, V. M. et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet \n                           387, 1531\u20131539 (2016).","journal-title":"Lancet"},{"key":"9797_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jcv.2016.10.024","volume":"85","author":"RS Azevedo","year":"2016","unstructured":"Azevedo, R. S. et al. Zika virus epidemic in Brazil. I. Fatal disease in adults: clinical and laboratorial aspects. J. Clin. Virol. \n                           85, 56\u201364 (2016).","journal-title":"J. Clin. Virol."},{"key":"9797_CR5","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMc1610613","volume":"375","author":"S Swaminathan","year":"2016","unstructured":"Swaminathan, S., Schlaberg, R., Lewis, J., Hanson, K. E. & Couturier, M. R. Fatal Zika virus infection with secondary nonsexual transmission. N. Engl. J. Med. \n                           375, 1907\u20131909 (2016).","journal-title":"N. Engl. J. Med."},{"key":"9797_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/051268","author":"R Delvecchio","year":"2016","unstructured":"Delvecchio, R. et al. Chloroquine inhibits Zika virus infection in different cellular models. bioRxiv preprint. doi:10.1101\/051268 (2016).","journal-title":"bioRxiv preprint"},{"key":"9797_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004695","volume":"10","author":"J Zmurko","year":"2016","unstructured":"Zmurko, J. et al. The viral polymerase inhibitor 7-deaza-2\u2032-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. \n                           10, e0004695 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"9797_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/infdis\/jiw226","volume":"214","author":"L Eyer","year":"2016","unstructured":"Eyer, L. et al. Nucleoside inhibitors of Zika virus. J. Infect. Dis. \n                           214, 707\u2013711 (2016).","journal-title":"J. Infect. Dis."},{"key":"9797_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","volume":"20","author":"NJ Barrows","year":"2016","unstructured":"Barrows, N. J. et al. A screen of FDA-approved drugs for inhibitors of zika virus infection. Cell Host Microbe \n                           20, 259\u2013270 (2016).","journal-title":"Cell Host Microbe"},{"key":"9797_CR10","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/jmv.24678","volume":"88","author":"AA Elfiky","year":"2016","unstructured":"Elfiky, A. A. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J. Med. Virol. \n                           88, 2044\u20132051 (2016).","journal-title":"J. Med. Virol."},{"key":"9797_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nm.4184","volume":"22","author":"M Xu","year":"2016","unstructured":"Xu, M. et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med. \n                           22, 1101\u20131107 (2016).","journal-title":"Nat. Med."},{"key":"9797_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","volume":"137","author":"KM Bullard-Feibelman","year":"2017","unstructured":"Bullard-Feibelman, K. M. et al. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res. \n                           137, 134\u2013140 (2017).","journal-title":"Antiviral Res."},{"key":"9797_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep40920","volume":"7","author":"CQ Sacramento","year":"2017","unstructured":"Sacramento, C. Q. et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci. Rep. \n                           7, 40920 (2017).","journal-title":"Sci. Rep."},{"key":"9797_CR14","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1016\/j.celrep.2016.08.038","volume":"16","author":"M Onorati","year":"2016","unstructured":"Onorati, M. et al. Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia. Cell Rep. \n                           16, 2576\u20132592 (2016).","journal-title":"Cell Rep."},{"key":"9797_CR15","doi-asserted-by":"publisher","first-page":"e00009","DOI":"10.1128\/JVI.00009-17","volume":"91","author":"TE Morrison","year":"2017","unstructured":"Morrison, T. E. & Diamond, M. S. Animal models of Zika virus infection, pathogenesis, and immunity. J. Virol. \n                           91, e00009\u201300017 (2017).","journal-title":"J. Virol."},{"key":"9797_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ng1665","volume":"37","author":"R Chia","year":"2005","unstructured":"Chia, R., Achilli, F., Festing, M. F. & Fisher, E. M. The origins and uses of mouse outbred stocks. Nat. Genet. \n                           37, 1181\u20131186 (2005).","journal-title":"Nat. Genet."},{"key":"9797_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.etp.2016.11.004","volume":"69","author":"NC Fernandes","year":"2017","unstructured":"Fernandes, N. C. et al. Experimental Zika virus infection induces spinal cord injury and encephalitis in newborn Swiss mice. Exp. Toxicol. Pathol. \n                           69, 63\u201371 (2017).","journal-title":"Exp. Toxicol. Pathol."},{"key":"9797_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1523\/JNEUROSCI.3124-16.2017","volume":"37","author":"AN van den Pol","year":"2017","unstructured":"van den Pol, A. N., Mao, G., Yang, Y., Ornaghi, S. & Davis, J. N. Zika virus targeting in the developing brain. J. Neurosci. \n                           37, 2161\u20132175 (2017).","journal-title":"J. Neurosci."},{"key":"9797_CR19","doi-asserted-by":"publisher","unstructured":"Stauft, C. B., Gorbatsevych, O., Cello, J., Wimmer, E. & Futcher, B. Comparison of African, Asian, and American Zika viruses in Swiss Webster mice: virulence, neutralizing antibodies, and serotypes. bioRxiv, doi:10.1101\/075747, 075747 (2016).","DOI":"10.1101\/075747"},{"key":"9797_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jviromet.2017.04.011","volume":"246","author":"SVA Coelho","year":"2017","unstructured":"Coelho, S. V. A. et al. Development of standard methods for Zika virus propagation, titration, and purification. J. Virol. Methods \n                           246, 65\u201374 (2017).","journal-title":"J. Virol. Methods"},{"key":"9797_CR21","unstructured":"Centers for Disease Control and Prevention (CDC). Revised diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories. https:\/\/www.cdc.gov\/zika\/pdfs\/denvchikvzikv-testing-algorithm.pdf (2016)."},{"key":"9797_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.joca.2012.02.010","volume":"20","author":"C Kilkenny","year":"2012","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarth. Cartil. \n                           20, 256\u2013260 (2012).","journal-title":"Osteoarth. Cartil."},{"key":"9797_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep34793","volume":"6","author":"WC Huang","year":"2016","unstructured":"Huang, W. C., Abraham, R., Shim, B. S., Choe, H. & Page, D. T. Zika virus infection during the period of maximal brain growth causes microcephaly and corticospinal neuron apoptosis in wild type mice. Sci. Rep. \n                           6, 34793 (2016).","journal-title":"Sci. Rep."},{"key":"9797_CR24","unstructured":"Dean, A. G., Sullivan, K. M. & Soe, M. M. OpenEpi: open source epidemiologic statistics for public health. www.OpenEpi.com (2014)."},{"key":"9797_CR25","unstructured":"European Medicines Agency, EMA. Sovaldi. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Public_assessment_report\/human\/002798\/WC500160600.pdf (2013)."},{"key":"9797_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ebiom.2016.09.020","volume":"12","author":"Y Simonin","year":"2016","unstructured":"Simonin, Y. et al. Zika virus strains potentially display different infectious profiles in human neural cells. EBioMedicine \n                           12, 161\u2013169 (2016).","journal-title":"EBioMedicine"},{"key":"9797_CR27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3201\/eid2207.160375","volume":"22","author":"J Cerbino-Neto","year":"2016","unstructured":"Cerbino-Neto, J. et al. Clinical manifestations of Zika virus infection, Rio de Janeiro, Brazil, 2015. Emerg. Infect. Dis. \n                           22, 1318\u20131320 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"9797_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nature22402","volume":"546","author":"HC Metsky","year":"2017","unstructured":"Metsky, H. C. et al. Zika virus evolution and spread in the Americas. Nature \n                           546, 411\u2013415 (2017).","journal-title":"Nature"},{"key":"9797_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1473-3099(16)00125-0","volume":"16","author":"T Solomon","year":"2016","unstructured":"Solomon, T., Baylis, M. & Brown, D. Zika virus and neurological disease-approaches to the unknown. Lancet Infect. Dis. \n                           16, 402\u2013404 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"9797_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","volume":"2","author":"SG Muthuri","year":"2014","unstructured":"Muthuri, S. G. et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir. Med. \n                           2, 395\u2013404 (2014).","journal-title":"Lancet Respir. Med."},{"key":"9797_CR31","unstructured":"Au-TGA, Australian Therapeutic Goods and Administration. Australian public assessment report for ledipasvir\/sofosbuvir. https:\/\/www.tga.gov.au\/auspar\/auspar-sofosbuvir-ledipasvir (2015)."},{"key":"9797_CR32","unstructured":"Study of Hepatitis C treatment during pregnancy - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02683005 (2017)."},{"key":"9797_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006219","volume":"13","author":"AJ Hirsch","year":"2017","unstructured":"Hirsch, A. J. et al. Zika virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. \n                           13, e1006219 (2017).","journal-title":"PLoS Pathog."},{"key":"9797_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004658","volume":"10","author":"SD Dowall","year":"2016","unstructured":"Dowall, S. D. et al. A susceptible mouse model for Zika virus infection. PLoS Negl. Trop. Dis. \n                           10, e0004658 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"9797_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613108","author":"G Paz-Bailey","year":"2017","unstructured":"Paz-Bailey, G. et al. Persistence of Zika virus in body fluids - preliminary report. N. Engl. J. Med. doi:10.1056\/NEJMoa1613108 (2017).","journal-title":"N. Engl. J. Med."},{"key":"9797_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.aaf6116","volume":"352","author":"PP Garcez","year":"2016","unstructured":"Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science \n                           352, 816\u2013818 (2016).","journal-title":"Science"},{"key":"9797_CR37","doi-asserted-by":"publisher","first-page":"14408","DOI":"10.1073\/pnas.1618029113","volume":"113","author":"H Retallack","year":"2016","unstructured":"Retallack, H. et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc. Natl. Acad. Sci. USA. \n                           113, 14408\u201314413 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09797-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09797-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09797-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T04:22:55Z","timestamp":1671769375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09797-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9797"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09797-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/129197","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]},"assertion":[{"value":"8 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.B. is a member of the consortium BMK, which manufactures sofosbuvir.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9409"}}